Recent studies have identified that N-methyladenosine (mA) extensively participates in the myocardial injury pathophysiological process. However, the role of mA on sepsis-induced myocardial injury is still unclear. Here, we investigated the functions and mechanism of mA methyltransferase METTL3 for septic myocardial injury. Results illustrated that the mA modification level and METTL3 up-regulated in the lipopolysaccharide (LPS)-induced cardiomyocytes (H9C2 cells). Methylated RNA immunoprecipitation sequencing (MeRIP-Seq) revealed the mA profile of the septic myocardial injury cellular model. Functionally, METTL3 knockdown repressed the inflammatory damage of cardiomyocytes induced by LPS. Mechanistically, we found that HDAC4 had remarkable mA modification sites on its 3'-UTR genome, acting as the downstream target of METTL3. Besides, mA reader IGF2BP1 recognized the mA modification sites on HDAC4 mRNA and enhanced its RNA stability. In conclusion, the findings illustrated a role of METTL3/IGF2BP1/mA/HDAC4 axis on sepsis-induced myocardial injury, which might provide novel therapeutic strategy for septic myocardial injury.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287338 | PMC |
http://dx.doi.org/10.1038/s41420-022-01099-x | DOI Listing |
Semin Thorac Cardiovasc Surg
January 2025
Department of Cardiothoracic Surgery, Metropolitan Heart and Vascular Institute, Coon Rapids, Minnesota.
Beating-heart CABG in patients with LV dysfunction can provide the best of all words by limiting myocardial injury purported by cardioplegic arrest. Complete revascularization is possible and graft numbers are not different when compared to arrested heart CABG. Furthermore, beating-heart CABG more often reduces the need for intraoperative and postoperative mechanical support reducing the complications and costs associated with these devices.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. Electronic address:
Mitochondrial dysfunction and ferroptosis play crucial roles in myocardial ischemia/reperfusion (I/R) following heart transplantation. Microsomal glutathione s transferase 1 (MGST1) is widely distributed in mitochondria and has a protective effect against ferroptosis, and its involvement in myocardial I/R injury has not yet been elucidated. In this study, donor hearts from C57BL/6 male mice were subjected to 12 h of ex-vivo cold ischemia treatment and transplanted into the abdomen of recipient mice for 24 h of reperfusion.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China. Electronic address:
Purpose: Targeting mitochondrial ferroptosis presents a promising strategy for mitigating myocardial ischemia-reperfusion (I/R) injury. This study aims to evaluate the efficacy of the mitochondrial-targeted ferroptosis inhibitor SS-31@Fer-1 (elamipretide@ferrostatin1) in reducing myocardial I/R injury.
Methods: SS-31@Fer-1 was synthesized and applied to H9C2 cells subjected to hypoxia/reoxygenation (H/R) to assess its protective effects.
ESC Heart Fail
January 2025
Department of Cardiology, Stavanger University Hospital, Stavanger, Norway.
Background: Cardiac myosin binding protein C (cMyC) is an emerging new biomarker of myocardial injury rising earlier and cleared faster than cardiac troponins. It has discriminatory power similar to high-sensitive troponins in diagnosing myocardial infarction in patients presenting with chest pain. It is also associated with outcome in patients with acute heart failure.
View Article and Find Full Text PDFJ Am Heart Assoc
January 2025
Department of Neurology with experimental Neurology (Klinik und Hochschulambulanz für Neurologie mit experimenteller Neurologie), Charité-Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!